CIMZIA ® is the only Fc-free, PEGylated anti-TNF (Tumor Necrosis Factor). CIMZIA ® has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha.

Belgian drugmaker UCB <UCBBt.BR> is still hoping to launch its Crohn's disease drug Cimzia in the United States in the first half of 2007 and does not think further clinical trials will be needed ...

Cimzia will compete against three existing anti-TNF drugs -- Amgen's Enbrel, Johnson & Johnson's Remicade and Abbott Laboratories Inc.'s Humira -- that can cost $10,000 to $30,000 per patient a year.

CIMZIA in combination methotrexate (MTX) is indicated for reducing signs and symptoms, inducing major clinical response, and reducing the progression of joint damage as assessed by X-ray, in adult ...

Initiate treatment for latent TB prior to CIMZIA use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis.

Cimzia's primary indication is for rheumatoid arthritis in adults as well as axial spondylarthrosis, psoriasis and Crohn's disease. In 2020 global sales of CIMZIA were 1.8 billion euros.